Literature DB >> 11244507

Mutations of the Smad4 gene in acute myelogeneous leukemia and their functional implications in leukemogenesis.

Y Imai1, M Kurokawa, K Izutsu, A Hangaishi, K Maki, S Ogawa, S Chiba, K Mitani, H Hirai.   

Abstract

The Smad family proteins are critical components of the transforming growth factor (TGF)-beta signaling pathway. TGF-beta is a multipotent cytokine that elicits many biological functions. In particular, TGF-beta exhibits effects on the cell cycle manifested by G1-phase arrest, differentiation, or apoptosis of several target cells, suggesting that disruption of TGF-beta signaling pathway could be involved in cancer formation. Here we show one missense mutation of the Smad4 gene in the MH1 domain (P102L) and one frame shift mutation resulting in termination in the MH2 domain (Delta(483 - 552)) in acute myelogeneous leukemia. Both of the mutated Smad4 proteins lack transcriptional activities. Concomitant expression of the P102L mutant with wild-type Smad4 inactivates wild-type Smad4 through inhibiting its DNA-binding ability. The Delta(483 - 552) mutant blocks nuclear translocation of wild-type Smad4 and thus disrupts TGF-beta signaling. This is the first report showing that mutations in the Smad4 gene are associated with the pathogenesis of acute myelogeneous leukemia and the obtained results should provide useful insights into the mechanism whereby disruption of TGF-beta signaling pathway could lead to acute myelogeneous leukemia. Oncogene (2001) 20, 88 - 96.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11244507     DOI: 10.1038/sj.onc.1204057

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  18 in total

Review 1.  Transforming growth factor (TGF)-β pathway as a therapeutic target in lower risk myelodysplastic syndromes.

Authors:  Jan Philipp Bewersdorf; Amer M Zeidan
Journal:  Leukemia       Date:  2019-04-08       Impact factor: 11.528

2.  Targeting Smad4 links microRNA-146a to the TGF-beta pathway during retinoid acid induction in acute promyelocytic leukemia cell line.

Authors:  Hua Zhong; Hai-rong Wang; Shuang Yang; Ji-hua Zhong; Ting Wang; Chun Wang; Fang-yuan Chen
Journal:  Int J Hematol       Date:  2010-06-25       Impact factor: 2.490

3.  Aberrant expression of Treg-associated cytokine IL-35 along with IL-10 and TGF-β in acute myeloid leukemia.

Authors:  Hao Wu; Peng Li; Na Shao; Jingjing Ma; Min Ji; Xiulian Sun; Daoxin Ma; Chunyan Ji
Journal:  Oncol Lett       Date:  2012-02-20       Impact factor: 2.967

4.  Tgf-Beta superfamily receptors-targets for antiangiogenic therapy?

Authors:  Jasmin Otten; Carsten Bokemeyer; Walter Fiedler
Journal:  J Oncol       Date:  2010-05-13       Impact factor: 4.375

5.  The corepressor mSin3A regulates phosphorylation-induced activation, intranuclear location, and stability of AML1.

Authors:  Yoichi Imai; Mineo Kurokawa; Yuko Yamaguchi; Koji Izutsu; Eriko Nitta; Kinuko Mitani; Masanobu Satake; Tetsuo Noda; Yoshiaki Ito; Hisamaru Hirai
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

6.  Homeoprotein DLX-1 interacts with Smad4 and blocks a signaling pathway from activin A in hematopoietic cells.

Authors:  Shigeru Chiba; Kenichi Takeshita; Yoichi Imai; Keiki Kumano; Mineo Kurokawa; Shigeo Masuda; Kiyoshi Shimizu; Shuji Nakamura; Frank H Ruddle; Hisamaru Hirai
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-11       Impact factor: 11.205

7.  Transforming growth factor beta-induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation.

Authors:  Joseph M Scandura; Piernicola Boccuni; Joan Massagué; Stephen D Nimer
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-11       Impact factor: 11.205

Review 8.  Role of transforming growth factor-beta in hematologic malignancies.

Authors:  Mei Dong; Gerard C Blobe
Journal:  Blood       Date:  2006-02-16       Impact factor: 22.113

9.  Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS.

Authors:  Li Zhou; Aaron N Nguyen; Davendra Sohal; Jing Ying Ma; Perry Pahanish; Krishna Gundabolu; Josh Hayman; Adam Chubak; Yongkai Mo; Tushar D Bhagat; Bhaskar Das; Ann M Kapoun; Tony A Navas; Simrit Parmar; Suman Kambhampati; Andrea Pellagatti; Ira Braunchweig; Ying Zhang; Amittha Wickrema; Satyanarayana Medicherla; Jacqueline Boultwood; Leonidas C Platanias; Linda S Higgins; Alan F List; Markus Bitzer; Amit Verma
Journal:  Blood       Date:  2008-05-12       Impact factor: 22.113

10.  TGFbeta/BMP inhibits the bone marrow transformation capability of Hoxa9 by repressing its DNA-binding ability.

Authors:  Ning Wang; Hyung-Gyoong Kim; Claudiu V Cotta; Mei Wan; Yi Tang; Christopher A Klug; Xu Cao
Journal:  EMBO J       Date:  2006-03-09       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.